Simulations Plus

As I mentioned last month, we are finally going to be attending a real conference, in-person, “non-virtually”!  Please stop by and visit us at our booth at AAPS PharmSci 360 on October...

Hooray!... We are finally going to be attending a real conference, in-person, “non-virtually”!

Coinciding with the milestone of our “silver anniversary” comes the news of the “passing of the torch”!

Thanks to all of you for the many contributions that you all have made over the years to help us reach the significant milestone of our “silver anniversary”.

The world is constantly changing, and with the advancement of technology, it is moving at an accelerated pace.

Kevin Dykstra answers questions like, "Why do we care about Drug Exposure?"

As I think back on 20+ years of lecturing on the population modeling & simulation (M&S) approach, I am simultaneously struck by how much has changed and how much has remained the same.

Our experience in data assembly is extensive: we’ve been building analysis-ready datasets for pharmacometric modeling and simulation for over 25 years.

A long time ago, in a desert far, far away…

We hope that you and yours are coming out of our Covid enforced isolation.

Is your compound causing drug-induced liver injury?

Did you know? We provide high-quality analysis & support services including non-compartmental PK analysis, population PK and PK/PD modeling, PBPK modeling in GastroPlus®, and statistical modeling, focusing on...

Phase 1 is a drug development stage where you start the clinical evaluation of the drug.

There has been an increasing desire to incorporate mechanistic models of in vitro experiments to evaluate the interplay between...